Literature DB >> 9530155

DNA methylation contributes to expression of the human neurotensin/neuromedin N gene.

Z Dong1, X Wang, Q Zhao, C M Townsend, B M Evers.   

Abstract

The gut and liver share a common embryological origin. The gene encoding the gut hormone neurotensin/neuromedin N (NT/N) is expressed in the adult small bowel, and NT/N is transiently expressed in the fetal liver, suppressed in the adult liver, and reexpressed in certain liver cancers. In our present study, we found that the NT/N gene was expressed at high levels in the human hepatoma cell line Hep 3B but was not expressed in Hep G2 cells. To further determine the mechanisms regulating NT/N expression, we performed Southern blotting and gene cloning techniques. Neither alteration nor mutation of the NT/N gene was responsible for this differential NT/N expression pattern. Human NT/N promoter constructs were transfected into either Hep 3B or Hep G2. Both cell lines supported NT/N transcription, indicating that the absence of NT/N expression in Hep G2 cells was due to mechanisms other than the absence of positive transcription factors. The role of DNA methylation was next assessed. Methylation of NT/N promoter constructs in vitro resulted in a 67-fold reduction in promoter activity, whereas treatment with the demethylating agent 5-azacytidine induced NT/N expression in Hep G2 cells, thus suggesting that DNA methylation plays a role in the expression of the gut endocrine gene NT/N. Defining the mechanisms regulating NT/N expression in these hepatic-derived cell lines will provide not only a better understanding of cell-specific and developmental regulation of a gut endocrine gene but also possible insight into liver cell lineage patterns and the derivation of certain hepatocellular cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9530155     DOI: 10.1152/ajpgi.1998.274.3.G535

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  Methylation status of c-fms oncogene in HCC and its relationship with clinical pathology.

Authors:  J Cui; D H Yang; X J Bi; Z R Fan
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.

Authors:  Jing Li; Jianyu Liu; Jun Song; Xiaofu Wang; Heidi L Weiss; Courtney M Townsend; Tianyan Gao; B Mark Evers
Journal:  Am J Physiol Cell Physiol       Date:  2011-04-20       Impact factor: 4.249

3.  Neurotensin, a novel target of Wnt/β-catenin pathway, promotes growth of neuroendocrine tumor cells.

Authors:  Ji Tae Kim; Chunming Liu; Yekaterina Y Zaytseva; Heidi L Weiss; Courtney M Townsend; B Mark Evers
Journal:  Int J Cancer       Date:  2014-08-14       Impact factor: 7.396

4.  EIF3 p170, a mediator of mimosine effect on protein synthesis and cell cycle progression.

Authors:  Zizheng Dong; Jian-Ting Zhang
Journal:  Mol Biol Cell       Date:  2003-05-29       Impact factor: 4.138

5.  Characterization of early developmental pattern of expression of neurotensin/neuromedin N gene in foregut and midgut.

Authors:  X M Wang; B M Evers
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

6.  Neurotensin receptor 1 is expressed in gastrointestinal stromal tumors but not in interstitial cells of Cajal.

Authors:  Petra Gromova; Brian P Rubin; An Thys; Christophe Erneux; Jean-Marie Vanderwinden
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

7.  Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells.

Authors:  Ji Tae Kim; Jing Li; Jun Song; Eun Y Lee; Heidi L Weiss; Courtney M Townsend; B Mark Evers
Journal:  Oncotarget       Date:  2015-09-29

8.  Diverse expression patterns and tumorigenic role of neurotensin signaling components in colorectal cancer cells.

Authors:  Ji Tae Kim; Heidi L Weiss; B Mark Evers
Journal:  Int J Oncol       Date:  2017-05-09       Impact factor: 5.650

9.  Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy.

Authors:  Zherui Wu; Daniel Martinez-Fong; Jean Trédaniel; Patricia Forgez
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-17       Impact factor: 5.555

10.  The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression.

Authors:  Sandra Dupouy; Véronique Viardot-Foucault; Marco Alifano; Frédérique Souazé; Geneviève Plu-Bureau; Marc Chaouat; Anne Lavaur; Danielle Hugol; Christian Gespach; Anne Gompel; Patricia Forgez
Journal:  PLoS One       Date:  2009-01-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.